Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, nCino
By Elias Schisgall
Intuit projected that sales growth would slow in the year ahead, weighed down by expected declines in the company's desktop business. The company may also accept short-term trade-offs in its business as it looks to boost TurboTax customers, its CFO told The Wall Street Journal. Shares fell 9.8% to $322.57 in after-hours trading on Tuesday.
Spyre Therapeutics said it will not prioritize developing one of its drug candidates as a monotherapy for rheumatoid arthritis after results from a trial missed its internal targets. The stock slid 11% to $95.09 after the bell.
Zoom Communications issued guidance for third-quarter adjusted earnings per share that missed Wall Street expectations. Shares were down 3.9% at $97.00.
NCino projected third-quarter revenue in a range with a midpoint below analyst expectations. The stock was down 5.6% at $19.65.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
August 25, 2026 19:20 ET (23:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States